Diabetic Macular Edema Pipeline Review H2 2015

1. Diabetic Macular Edema - Pipeline Review, H2 2015 By RnRMarketResearch.com Publisher Name : Global Markets Direct Date: 21-Oct-2015 No. of pages: 199 Single User License: US $2000 Browse more Reports on Ophthalmology therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/ophthalmology-therapeutics . ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

2. Diabetic Macular Edema - Pipeline Review, H2 2015 This report provides comprehensive information on the therapeutic development for Diabetic Macular Edema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Macular Edema and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

3. Diabetic Macular Edema - Pipeline Review, H2 2015 Companies Discussed/Mentioned in this Research: Aciont Inc., ActiveSite Pharmaceuticals, Inc., Acucela Inc., Aerpio Therapeutics, Inc., Allergan Plc, Ampio Pharmaceuticals, Inc., Astellas Pharma Inc., Avalanche Biotechnologies, Inc., Chengdu Kanghong Pharmaceuticals Group Co., Ltd., Chong Kun Dang Pharmaceutical Corp., Dyax Corp., EyeGate Pharmaceuticals, Inc., EyeGene, Inc., F. Hoffmann-La Roche Ltd., Gene Signal International SA, Genmab A/S, Icon Bioscience, Inc., Kala Pharmaceuticals, Inc., Kowa Company, Ltd., Mabion SA, MacuCLEAR, Inc., NicOx S.A., Oculisehf, Ohr Pharmaceutical Inc., Pfizer Inc., Quark Pharmaceuticals, Inc., R-Tech Ueno, Ltd., Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., SciFluor Life Sciences, LLC, Senju Pharmaceutical Co., Ltd., ThromboGenics NV and Verseon Corporation Drugs Profile Discussed in this Research: aganirsen, AKB-9778, ALG-1001, Antibodies to Inhibit Hemopexin for Diabetic Macular Edema, ASP-440, ASP-8232, AVA-101, conbercept, danazol, dexamethasone acetate, dexamethasone dipropionate, difluprednate, Drug for Diabetic Macular Edema, Drugs to Inhibit Semaphorin 3A for Diabetic Macular Edema, Drugs to Inhibit Tyrosine Kinase for Ophthalmology, EG-Mirotin, emixustat hydrochloride, KVD-001, lanadelumab, LKA-651, loteprednoletabonate, MC-4001, methotrexate, MTP-131, NCX-422, NCX-434, nesvacumab, NM-108, ocriplasmin (recombinant), OLX-303, PF-04634817, PF-655, ranibizumab, ranibizumab biosimilar, ranibizumabbiosimilar and more.. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

4. Diabetic Macular Edema - Pipeline Review, H2 2015 Scope For Diabetic Macular Edema - Pipeline Review, H2 2015 • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities • The report reviews key players involved in the therapeutics development for Diabetic Macular Edema and enlists all their major and minor projects • The report summarizes all the dormant and discontinued pipeline projects • A review of the Diabetic Macular Edema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages • A detailed assessment of monotherapy and combination therapy pipeline projects • Coverage of the Diabetic Macular Edema pipeline on the basis of target, MoA, route of administration and molecule type ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

5. Diabetic Macular Edema - Pipeline Review, H2 2015 Reasons to Buy: • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage • Develop strategic initiatives by understanding the focus areas of leading companies • Identify and understand important and diverse types of therapeutics under development for Diabetic Macular Edema • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline • Devise corrective measures for pipeline projects by understanding Diabetic Macular Edema pipeline depth and focus of Indication therapeutics • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

6. Diabetic Macular Edema - Pipeline Review, H2 2015 For more details contact Mr. Ritesh Tiwari :sales@rnrmarketresearch.com/ +18883915441 RnRMarkertResearch RnRMarketResearch.com, an online repository of market  research reports, offers in-depth analysis of over 5000 market segments. RnRMarket Research library has syndicated reports by leading market research  publishers across the globe. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441